Who
Carmine N. Stengone
CEO and President
Company insider
Files Form 4 as: CEO and President, Contineum Therapeutics; Director, Kiora Pharmaceuticals.
In numbers
- Trades disclosed
- 56
- Buys
- 1
- Sells
- 7
- Bought
- $4,600
- Sold
- $803K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 Sep 2023
- Last trade
- 8 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 8 Sep 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,5252,500 at $1.01 | filing |
| 8 Sep 2026filed 8 Sep 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K2,500 at $16.46 | filing |
| 8 Sep 2026filed 8 Sep 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,5252,500 at $1.01 | filing |
| 8 Sep 2026filed 8 Sep 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K2,500 at $16.46 | filing |
| 3 Aug 2026filed 3 Aug 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,5252,500 at $1.01 | filing |
| 3 Aug 2026filed 3 Aug 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K2,500 at $16.01 | filing |
| 3 Aug 2026filed 3 Aug 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,5252,500 at $1.01 | filing |
| 3 Aug 2026filed 3 Aug 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K2,500 at $16.01 | filing |
| 8 Jul 2026filed 8 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,5252,500 at $1.01 | filing |
| 8 Jul 2026filed 8 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K2,500 at $16.00 | filing |
| 8 Jul 2026filed 8 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 8 Jul 2026filed 8 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 8 Jul 2026filed 8 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,5252,500 at $1.01 | filing |
| 8 Jul 2026filed 8 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K2,500 at $16.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $7,5757,500 at $1.01 | filing |
| 30 Jun 2026filed 1 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,1502,500 at $1.26 | filing |
News
Contineum Therapeutics (NASDAQ:CTNM) Reaches New 1-Year Low – Time to Sell?CTNM · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Carmine N. Stengone; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.